Compare Devon Energy Corp (DVN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Sanofi SA — how do they compare? Devon Energy Corp trades at $48.65 (market cap $53.81B), while Sanofi SA trades at $40.14 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Sanofi SA for 94 Days on average.
| DVN | SNY | |
|---|---|---|
Market Cap | $53.81B | $95.18B |
Volume | 11,556,740 | 2,995,646 |
Sector | Energy | Health |
52-Week High | $52.07 | $52.34 |
52-Week Low | $31.74 | $39.51 |
Typical Hold Time | 136 Days | 94 Days |
Enterprise Value | $64.55B | $114.48B |
Dividend Yield | 2.62% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.69, up 1.69% today, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 10.63, net income margin of 16.67%, and positive cash flow trends. Recent news highlights activist investor pressure for strategic alternatives, including a potential sale, amid ongoing M&A interest from firms like BP.
The outlook is positive, driven by valuation discounts, earnings beats, and potential asset sales, but risks include oil price volatility and execution challenges. Analyst consensus is strongly bullish with a $62.53 price target, suggesting significant upside from current levels.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
